BBIO · XBRL financial data

BridgeBio Pharma financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (BBIO's year ends in late December)

In millions of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Revenue from contracts with customers	2*	211	2	3	6*	117	111	121	154*	195	244	353
Cost of revenue	1*	1	1	1	year only	3	4	7	8*	10	15	20
Research and development	130*	141	115	120	130*	111	111	113	116*	127	149	144
Selling, general and administrative	48*	66	60	69	95*	106	129	138	158*	164	186	201
Operating income (loss)	(177)*	0	(176)	(192)	(226)*	(104)	(134)	(145)	(140)*	(106)	(107)	(12)
Interest income	6*	4	5	3	5*	5	4	6	4*	6	7	13
Interest expense	20*	23	23	23	30*	42	38	12	12*	13	13	13
Other income (expense)	22*	9	(1)	2	2*	8	7	16	12*	4	6	2
Income tax expense (benefit)	0*	0	0	0	1*	0	2	(2)	(0)*	—	0	1
Net income (loss)	—	—	—	—	—	—	—	(183)	—	—	—	(57)
Earnings per share, basic USD per share	—	(0.20)	(0.39)	(0.86)	—	(0.88)	(0.95)	(0.95)	—	(0.84)	(0.78)	(0.42)
Earnings per share, diluted USD per share	—	(0.20)	(0.39)	(0.86)	—	(0.88)	(0.95)	(0.95)	—	(0.84)	(0.78)	(0.42)
Weighted average shares, basic millions of shares	174*	179	188	189	189*	190	191	192	194*	195	196	196
Weighted average shares, diluted millions of shares	174*	179	188	189	189*	190	191	192	194*	195	196	196

Fiscal quarters (BBIO's year ends in late December)

In millions of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Cash and cash equivalents	376	475	408	266	681	541	749	643	570	880	678	1,533
Marketable securities	0	44	40	—	0	—	8	3	17	60	42	5
Accounts receivable	2	—	—	—	5	115	77	117	139	205	254	375
Inventory	—	—	—	—	0	4	18	25	27	33	53	60
Prepaid and other current assets	24	28	28	38	35	35	60	52	44	63	66	71
Total current assets	478	783	616	445	721	695	912	839	798	1,241	1,093	2,045
Property and equipment, net	12	11	10	9	7	7	6	6	5	5	5	5
Right-of-use asset	8	8	7	6	6	7	6	7	8	17	17	16
Total assets	546	849	794	665	919	882	1,080	998	936	1,371	1,217	2,162
Accounts payable	11	5	18	13	10	28	26	19	36	29	27	88
Total current liabilities	144	141	134	139	154	152	176	217	288	816	891	977
Long-term debt	446	435	435	436	437	0	0	—	—	—	—	—
Lease liability, non-current	9	8	7	6	5	5	4	3	4	14	15	15
Total liabilities	1,889	1,886	1,876	1,883	2,377	2,520	2,859	2,921	3,013	3,640	3,723	3,815
Accumulated deficit	(2,561)	(2,596)	(2,669)	(2,831)	(3,096)	(3,264)	(3,446)	(3,628)	(3,821)	(3,985)	(4,137)	(4,194)
Total stockholders' equity	(1,354)	(1,050)	(1,093)	(1,230)	(1,468)	(1,648)	(1,788)	(1,933)	(2,087)	(2,278)	(2,515)	(1,662)
Total liabilities and equity	546	849	794	665	919	882	1,080	998	936	1,371	1,217	2,162
Common shares outstanding (cover page) millions of shares	176	187	188	189	190	190	191	193	194	196	195	195

Fiscal quarters (BBIO's year ends in late December)

In millions of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Net income (loss)	—	—	—	—	—	—	—	(183)	—	—	—	(57)
Stock-based compensation	37*	17	21*	27*	30*	26	37*	35*	35*	33	44*	40*
Depreciation and amortization	2*	2	2*	2*	1*	1	1*	1*	1*	1	1*	1*
Net cash from operating activities	(125)*	(220)	75*	(181)*	(195)*	(199)	(81)*	(110)*	(56)*	(197)	(71)*	(44)*
Purchases of property and equipment	0*	1	0*	0*	0*	0	1*	0*	0*	0	0*	0*
Net cash from investing activities	(0)*	23	3*	38*	(3)*	(2)	(13)*	4*	(14)*	(43)	18*	37*
Proceeds from issuing common stock	0*	315	(0)*	(0)*	0*	0	0*	0*	0*	—	—	—
Share repurchases	year only	0	0*	0*	0*	48	0*	0*	0*	83	128*	42*
Proceeds from long-term debt	—	450	0*	0*	—	—	—	—	—	—	—	—
Repayments of long-term debt	0*	473	0*	0*	0*	459	0*	—	—	—	—	—
Net cash from financing activities	(5)*	280	(6)*	1*	474*	60	302*	(1)*	(2)*	550	(149)*	863*
Net change in cash	(129)*	83	72*	(142)*	275*	(141)	208*	(106)*	(73)*	310	(202)*	855*

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
BridgeBio Pharma	1,533	353	(44)*	194.8M	14.7 quarters	Q3 FY26 10-QSep 30, 2026
Biomarin Pharmaceutical	736	1,025	188*	193.7M	—	Q3 FY26 10-QSep 30, 2026
Revolution Medicines	815	not reported	(387)*	214.3M	10.2 quarters	Q2 FY26 10-QJun 30, 2026
Jazz Pharmaceuticals	2,036	1,243	506*	64.2M	—	Q3 FY26 10-QSep 30, 2026
Corcept Therapeutics	99	340	143*	109.4M	—	Q3 FY26 10-QSep 30, 2026
Repligen	727	209	43*	63.9M	—	Q3 FY26 10-QSep 30, 2026
BIO-TECHNE	265	321*	95*	156.8M	—	Q4 FY26 10-KJun 30, 2026
Exelixis	305	659	280*	244.0M	—	Q3 FY26 10-QOct 2, 2026
Madrigal Pharmaceuticals	515	431	121*	23.2M	—	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.